Evidence map›Paper›PMID 38238035›Full record

ArticleJournal of psychiatry & neuroscience : JPN

Different levels of prepulse inhibition among patients with first-episode schizophrenia, bipolar disorder and major depressive disorder.

Yue Sun, Qijing Bo, Zhen Mao, Qing Tian, Fang Dong, Liang Li, Chuanyue Wang

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of psychiatry & neuroscience : JPN. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Yue Sun *From the National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders, and Beijing Institute for Brain Disorders Center of Schizophrenia, Beijing Anding Hospital, Capital Medical University (Sun, Bo, Mao, Tian, Dong, Wang); the Advanced Innovation Center for Human Brain Protection, Capital Medical University (Sun, Bo, Mao, Tian, Dong, Wang); the School of Psychological and Cognitive Sciences and Beijing Key Laboratory of Behavior and Mental Health, Peking University, Beijing, China (Li).
Qijing Bo *From the National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders, and Beijing Institute for Brain Disorders Center of Schizophrenia, Beijing Anding Hospital, Capital Medical University (Sun, Bo, Mao, Tian, Dong, Wang); the Advanced Innovation Center for Human Brain Protection, Capital Medical University (Sun, Bo, Mao, Tian, Dong, Wang); the School of Psychological and Cognitive Sciences and Beijing Key Laboratory of Behavior and Mental Health, Peking University, Beijing, China (Li).
Zhen MaoFrom the National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders, and Beijing Institute for Brain Disorders Center of Schizophrenia, Beijing Anding Hospital, Capital Medical University (Sun, Bo, Mao, Tian, Dong, Wang); the Advanced Innovation Center for Human Brain Protection, Capital Medical University (Sun, Bo, Mao, Tian, Dong, Wang); the School of Psychological and Cognitive Sciences and Beijing Key Laboratory of Behavior and Mental Health, Peking University, Beijing, China (Li).
Qing TianFrom the National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders, and Beijing Institute for Brain Disorders Center of Schizophrenia, Beijing Anding Hospital, Capital Medical University (Sun, Bo, Mao, Tian, Dong, Wang); the Advanced Innovation Center for Human Brain Protection, Capital Medical University (Sun, Bo, Mao, Tian, Dong, Wang); the School of Psychological and Cognitive Sciences and Beijing Key Laboratory of Behavior and Mental Health, Peking University, Beijing, China (Li).
Fang DongFrom the National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders, and Beijing Institute for Brain Disorders Center of Schizophrenia, Beijing Anding Hospital, Capital Medical University (Sun, Bo, Mao, Tian, Dong, Wang); the Advanced Innovation Center for Human Brain Protection, Capital Medical University (Sun, Bo, Mao, Tian, Dong, Wang); the School of Psychological and Cognitive Sciences and Beijing Key Laboratory of Behavior and Mental Health, Peking University, Beijing, China (Li).
Liang LiFrom the National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders, and Beijing Institute for Brain Disorders Center of Schizophrenia, Beijing Anding Hospital, Capital Medical University (Sun, Bo, Mao, Tian, Dong, Wang); the Advanced Innovation Center for Human Brain Protection, Capital Medical University (Sun, Bo, Mao, Tian, Dong, Wang); the School of Psychological and Cognitive Sciences and Beijing Key Laboratory of Behavior and Mental Health, Peking University, Beijing, China (Li) wcyadyy@163.com liangli@pku.edu.cn.
Chuanyue WangFrom the National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders, and Beijing Institute for Brain Disorders Center of Schizophrenia, Beijing Anding Hospital, Capital Medical University (Sun, Bo, Mao, Tian, Dong, Wang); the Advanced Innovation Center for Human Brain Protection, Capital Medical University (Sun, Bo, Mao, Tian, Dong, Wang); the School of Psychological and Cognitive Sciences and Beijing Key Laboratory of Behavior and Mental Health, Peking University, Beijing, China (Li) wcyadyy@163.com liangli@pku.edu.cn.
Beijing Anding Hospital · CNNational Clinical Research · USPeking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDeficits in prepulse inhibition may be a common feature in first-episode schizophrenia, bipolar disorder (BD) and major depressive disorder (MDD). We sought to explore the levels and viability of prepulse inhibition to differentiate first-episode schizophrenia, BD and MDD in patient populations.

methodsWe tested patients with first-episode schizophrenia, BD or MDD and healthy controls using prepulse inhibition paradigms, namely perceived spatial co-location (PSC-PPI) and perceived spatial separation (PSS-PPI).

resultsWe included 53 patients with first-episode schizophrenia, 30 with BD and 25 with MDD, as well as 82 healthy controls. The PSS-PPI indicated that the levels of prepulse inhibition were smallest to largest, respectively, in the first-episode schizophrenia, BD, MDD and control groups. Relative to the healthy controls, the prepulse inhibition deficits in the first-episode schizophrenia group were significant ( LIMITATIONS: The demographics of the 4 groups were not ideally matched. We did not perform cognitive assessments. The possible confounding effect of medications on prepulse inhibition could not be eliminated.

conclusionThe level of prepulse inhibition among patients with first-episode schizophrenia was the lowest, with levels among patients with BD, patients with MDD and healthy controls increasingly higher. The PSS-PPI paradigm was more effective than PSC-PPI to recognize deficits in prepulse inhibition. These results provide a basis for further research on biological indicators that can assist differential diagnoses in psychosis.

Indexed as

Bipolar DisorderMajor Depressive DisorderSchizophreniaCase-Control StudiesHumansPrepulse Inhibition

Identifiers

PMID38238035
PMCPMC10803101
OpenAlexW4390985218

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.